Sumitomo Pharma Canada, Inc., announced today that ORGOVYX® (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is now available for prescription in Canada for the treatment of adult patients with advanced prostate cancer. The availability of ORGOVYX follows the Health Canada approval of ORGOVYX in October 2023 for the treatment of advanced prostate cancer.
“Lowering the body’s testosterone level is a first-line treatment approach for men with advanced prostate cancer,” said Fred Saad, M.D., FRCS, Professor and Chairman of the Department of Surgery and Director of Genitourinary Oncology at the University of Montreal. “Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares.”
The Health Canada approval of ORGOVYX was based on efficacy and safety data from the Phase 3 HERO study in men with advanced prostate cancer. In the Phase 3 HERO study, 97% of men who received ORGOVYX lowered their testosterone (< 50 ng/dL) by Day 29 through Week 48, compared to 89% of those who received leuprolide acetate injections. The most frequent adverse events reported in at least 10% of men in the ORGOVYX group were hot flush, musculoskeletal pain, fatigue, constipation, and diarrhea.
“An estimated 24,700 Canadian men were diagnosed with prostate cancer last year, making the disease the most common cancer experienced by men in the country,” said Lisa Mullett, SVP, General Manager of Sumitomo Pharma Canada, Inc. “With the availability of ORGOVYX as of today, we are pleased to offer Canadian physicians an oral GnRH antagonist treatment option with proven safety and tolerability for their patients with advanced prostate cancer.”
About Advanced Prostate Cancer
Prostate cancer is the most common cancer in Canadian men, and, in 2023 approximately 24,700 men were diagnosed.1 Prostate cancer is considered advanced when it has spread or come back after initial treatment and may include biochemical recurrence (rising prostate-specific antigen in the absence of metastatic disease on imaging), locally advanced disease, or metastatic disease.
Front-line medical therapy for advanced prostate cancer typically involves androgen deprivation therapy, which reduces testosterone to very low levels, commonly referred to as castrate levels (< 50 ng/dL). Luteinizing hormone-releasing hormone (LHRH) receptor agonists, such as leuprolide acetate, are depot injections and the current standard of care for androgen deprivation therapy. LHRH receptor agonists may be associated with mechanism-of-action limitations, including an initial surge in testosterone levels that may exacerbate clinical symptoms, which is known as clinical or hormonal flare, and potentially delayed testosterone recovery after the drug is discontinued.
About ORGOVYX® (relugolix)
ORGOVYX (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration, the European Commission, and Health Canada for the treatment of adult patients with advanced prostate cancer. As a GnRH antagonist, ORGOVYX blocks the GnRH receptor, thereby reducing the release of the luteinizing and follicle-stimulating hormones, and consequently reducing the production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer.
About Sumitomo Pharma
Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma Canada, Inc.) and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing patient needs in psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner.
The Sumitomo Pharma icon is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license.
SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license.
Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd.
ORGOVYX is a trademark of Sumitomo Pharma Switzerland GmbH.
https://www.prnewswire.com/news-releases/sumitomo-pharma-announces-availability-of-orgovyx-relugolix-in-canada-the-first-and-only-oral-androgen-deprivation-therapy-treatment-for-men-with-advanced-prostate-cancer-302086280.html
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Groundbreaking CoCas9 Enzyme Unveiled: A Compact and Efficient CRISPR Tool for Genetic Therapy
Introduction: A revolutionary stride has been made in the field of genetic engineering, as researchers from the University of Trento introduce a novel CRISPR enzyme, CoCas9, which promises to enhance the delivery and efficacy of in vivo gene therapy using...
Pfizer’s New Gene Therapy BEQVEZ™ Wins FDA Approval for Hemophilia B
In a notable advancement for hemophilia treatment, Pfizer Inc. (NYSE: PFE) has received U.S. Food and Drug Administration approval for BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy aimed at adults suffering from moderate to severe hemophilia B. This...
Astellas Teams Up with Poseida Therapeutics for Innovative CAR-T Cell Therapy Development
Astellas Pharma, through its subsidiary Xyphos Biosciences, has entered into a second collaborative agreement with Poseida Therapeutics to pioneer the development of off-the-shelf cell therapies for solid tumors. This follows their initial partnership in 2023, which...
Cytiva Introduces New Cell Manufacturing Lines for Viral Vectors
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence of established standardized processes, resulting in high costs and...
Related Services
Plasmids GMP Services
AAV GMP Services
